Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 13/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861836 | 0.82 | MAPT (0.52) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL29540110 | 0.80 | DPP4 (0.33) | ALDH1A1MAPTFNTAFNTBPGGT1B | |
| SCHEMBL29379421 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1PMP22KMT2A | |
| SCHEMBL29527816 | 0.79 | ACE (0.56) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL30861862 | 0.78 | FNTA (0.48) | ALDH1A1MAPTPTGS1FNTAFNTB | |
| SCHEMBL29683631 | 0.78 | FOLH1 (0.50) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL9821227 | 0.77 | ACE (0.59) | ALDH1A1MAPTFNTAFNTBPGGT1B | |
| SCHEMBL29692973 | 0.77 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1ENPEP | |
| SCHEMBL30744301 | 0.77 | ENPEP (0.40) | FNTAFNTBPGGT1BENPEP | |
| SCHEMBL29378196 | 0.76 | ECE1 (0.51) | ALDH1A1MAPTPTGS1ENPEPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885MAPT 3614/4885PTGS1 3813/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885MAPT 3614/4885PTGS1 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.